Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents / Soghra Farzipour, Zahra Shaghaghi, Sahar Abbasi, Hajar Albooyeh, Maryam Alvandi
One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells. 225 Ac, 212 Bi, 211 At, 213 Bi, and 223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery residual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affinity of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 22(2022), 8, Seite 15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Farzipour, Soghra [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (15 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011155361 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011155361 | ||
| 003 | DE-627 | ||
| 005 | 20231128154808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011155361 | ||
| 035 | |a (KFL)prod_DARH_.42A3E41A0DFB3D27625905F38EE03F74CDD9E2F3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Farzipour, Soghra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents |c Soghra Farzipour, Zahra Shaghaghi, Sahar Abbasi, Hajar Albooyeh, Maryam Alvandi |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (15 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells. 225 Ac, 212 Bi, 211 At, 213 Bi, and 223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery residual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affinity of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches | ||
| 700 | 1 | |a Shaghaghi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Albooyeh, Hajar |e verfasserin |4 aut | |
| 700 | 1 | |a Alvandi, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d Sharjah : Bentham Sc. Publ., 2006 |g 22(2022), 8, Seite 15 |h Online-Ressource |w (DE-627)KFL000006505 |w (DE-600)2253831-8 |w (DE-576)273890913 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:8 |g pages:15 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5206&volume=22&issue=8&spage=1496 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 8 |h 15 | ||